Maria Markarian, DO
Interventional Cardiology · Lansing, MINPI 1861490641
Payments from drug & device makers
Across 877 payments — averaging $25.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Novartis$2K
- AstraZeneca$2K
- Amgen$2K
- Bayer$2K
- Boehringer Ingelheim$1K
- plus $10K from 30 others
What the payments were for
- Travel & lodging$6043%
- Food & beverage$21,56497%
- Education$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 104 | $2,789 |
| Novartis | 122 | $2,285 |
| AstraZeneca | 76 | $2,249 |
| Amgen | 95 | $1,903 |
| Bayer | 59 | $1,614 |
| Boehringer Ingelheim | 49 | $1,217 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 49 | $1,083 |
| Boston Scientific | 15 | $1,069 |
| Merck | 42 | $1,034 |
| Abbott | 16 | $1,003 |
| Amarin Pharma, Inc. | 35 | $871 |
| Pfizer | 32 | $870 |
| Esperion Therapeutics, Inc. | 39 | $625 |
| Regeneron Healthcare Solutions, Inc. | 24 | $522 |
| Novo Nordisk | 14 | $479 |
| Sanofi-aventis U.S. LLC | 8 | $475 |
| Lexicon Pharmaceuticals, Inc. | 21 | $323 |
| E.r. Squibb & Sons, L.L.C. | 16 | $307 |
| Biotronik Inc. | 3 | $178 |
| Alnylam Pharmaceuticals Inc. | 6 | $166 |
| Baxter Healthcare | 11 | $153 |
| Medtronic | 2 | $144 |
| Gilead | 9 | $131 |
| Shockwave Medical, Inc | 2 | $128 |
| Kowa Pharmaceuticals America, Inc. | 8 | $112 |
| Abiomed | 2 | $76 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $68 |
| Lundbeck LLC | 4 | $66 |
| Inspire Medical Systems, Inc. | 3 | $64 |
| Heartflow, Inc. | 1 | $45 |
| Lilly USA, LLC | 2 | $37 |
| Teleflex LLC | 2 | $37 |
| Philips North America LLC | 1 | $26 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Medicomp Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,207 in reported general payments places this provider in the 65th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 159 | $248,200 |
| XareltoRivaroxaban | 196 | $234,218 |
| EntrestoSacubitril/Valsartan | 75 | $117,883 |
| Repatha SureclickEvolocumab | 49 | $58,678 |
| NexletolBempedoic Acid | 36 | $36,811 |
| VerquvoVericiguat | 15 | $28,085 |
| MultaqDronedarone Hcl | 11 | $25,752 |
| OzempicSemaglutide | 16 | $25,227 |
| JardianceEmpagliflozin | 14 | $24,706 |
| NexlizetBempedoic Acid/Ezetimibe | 23 | $23,694 |
| KerendiaFinerenone | 22 | $22,964 |
| FarxigaDapagliflozin Propanediol | 14 | $22,932 |
| BrilintaTicagrelor | 23 | $17,828 |
| RybelsusSemaglutide | 14 | $15,341 |
| VascepaIcosapent Ethyl | 18 | $10,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $870 | $248,200159 claims |
| Johnson & JohnsonXarelto | $2,789 | $234,218196 claims |
| NovartisEntresto | $2,285 | $117,88375 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $625 | $60,50559 claims |
| AstraZenecaFarxiga, Brilinta | $2,249 | $40,76037 claims |
| Novo NordiskOzempic, Rybelsus | $479 | $40,56930 claims |
| MerckVerquvo | $1,034 | $28,08515 claims |
| Sanofi-aventis U.S. LLCMultaq | $475 | $25,75211 claims |
| Boehringer IngelheimJardiance | $1,217 | $24,70614 claims |
| BayerKerendia | $1,614 | $22,96422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Lansing
- Nam ChoLansing$285K
- Joel CohnLansing$122K
- Mohammed QintarLansing$59K
- Amir KakiDetroit$2.3M
- William MerhiGrand Rapids$2M
- Shukri DavidSouthfield$1.6M
- Qaiser ShafiqSouthgate$1.3M
- Marcel ZughaibSouthfield$1.2M
- Jason RicciPetoskey$1.1M
- Khaldoon AlaswadDetroit$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.